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Background/Purpose: Psychotropics are administered to control behavioral and psychological symptoms
of dementia. In 2005, the Food and Drug Administration (FDA) issued alerts regarding their use as an-
tipsychotics in elderly patients with dementia-related psychosis. Guidelines on psychotropic use were
also recently established in Japan; however, few studies have reported on the actual usage of psycho-
tropics among patients with dementia in clinical settings. The aim of this study was to estimate the
frequency of psychotropic use in patients with Alzheimer's disease receiving donepezil.
Methods: Data from six prospective, postmarketing studies of donepezil in patients with Alzheimer's
disease conducted between 1999 and 2011 were pooled for analysis. Patient and clinical characteristics at
baseline were analyzed descriptively. The proportion of psychotropics used concomitantly with done-
pezil was calculated for all patients and for patients divided into types of psychotropics used, sex, age,
and study time period. As for the study time period, studies were divided into two groups: the period
before the FDA alert was issued (1994e2004) and the period after (2005e2011).
Results: A total of 14,726 patients were analyzed (67.0% women, aged 79.3 ± 7.2 years). The overall
proportion of psychotropic use was 24.2%. The number of psychotropics used was one in 8.2% of patients,
two in 8.1%, and  3 in 5.5%. The types of psychotropics used were as follows: typical antipsychotics,
7.8%; atypical antipsychotics, 4.4%; antidepressants, 5.7%; anxiolytics, 6.4%; and hypnotics, 11.0% (% does
not sum up to 24.2% due to multiple use). With regards to the time periods, in studies conducted be-
tween 1999 and 2004 versus those between 2005 and 2011, the proportions were 31.7% and 21.3%,
respectively.
Conclusion: Psychotropic use was seen in a quarter of patients with dementia receiving donepezil in
Japan. Additionally, the overall proportion decreased after the alert issued by the FDA in 2005.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Dementia is a disease with core symptoms of cognitive deﬁcits
that are usually accompanied by noncognitive symptoms such as
behavioral abnormalities and psychological symptoms. These
noncognitive symptoms, referred to as Behavioral and Psychologi-
cal Symptoms of Dementia (BPSD), include psychotic symptoms,
such as verbal aggression, physical aggression, anxiety,a 4-6-10, Bunkyo-ku, Tokyo
ji).
inical Gerontology & Geriatrics. Pub
d/4.0/).hallucination, and delusion; sleep disorders; wandering; and
deﬁant behavior.1 It is reported that BPSD is observed in ~60e90%
of patients with dementia.2e7
BPSD deteriorates the quality of life of patients more than the
cognitive impairment, the hallmark of dementia, does. Conse-
quently, caregiver burden increases due to increased levels of
patient behavior disturbance.8 When patients' BPSD becomes
burdensome to caregivers, treatment of BPSD is required. If BPSD is
relatively mild, nonpharmacological treatment can alleviate the
symptoms. However, if BPSD is moderate to severe, or the symp-
toms impair the caregivers' quality of life, pharmacological treat-
ment is necessary in many cases. Although psychotropic agents are
currently used to treat BPSD, no speciﬁc pharmaceutical productslished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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Administration (FDA) warned that atypical antipsychotics, a type of
psychotropic, are associated with an increased risk of mortality in
elderly patients treated for dementia-related psychosis.9 Similarly,
in 2008, the FDA warned that typical antipsychotics are also asso-
ciated with an increased risk of mortality.10
Following the 2005 FDA alert, the package inserts of atypical
antipsychotics were revised in 2005,11 and following the 2008 FDA
alert, the package inserts of all antipsychotics were revised in
2009.12 In 2013, the Ministry of Health, Labor, and Welfare issued a
guideline for the use of psychotropics for BPSD.13 The guideline
states that, since treatment of BPSD with antipsychotics is an off-
label use, it is necessary to consider that psychotropics should
basically not be used and that the ﬁrst-line treatment should be
nonpharmacological intervention, in principle.
In Japan, it is estimated that there are > 4 million elderly people
with dementia;14 the number is expected to increase with the
future aging of the population. Among dementia, Alzheimer's dis-
ease (AD) is the most common form of dementia. Donepezil hy-
drochloride (Aricept®; Eisai Co., Ltd., Tokyo, Japan), the ﬁrst drug for
AD in Japan, was approved in 1999 with the indication of pre-
venting the progression of symptoms of dementia in patients with
mild or moderate AD. In 2007, the administration of 10 mg/d for
severe AD was also approved. Postmarketing, real-world data on
the use of donepezil hydrochloride in patients with any stage of AD
are available to date.
A recent study investigating the antipsychotic use among
> 13,000 elderly AD outpatients who were newly administered
with donepezil hydrochloride between 2007 and 2009 in Japan
using a prescription database reported that 8.9% were prescribed
with antipsychotics, predominantly atypical agents.15 Of these pa-
tients treated with antipsychotics, in round numbers, 11% received
combinations of antipsychotics, and 44% continued the treatment
for> 3months after the alerts issued by FDA andMinistry of Health,
Labor, and Welfare since 2005. To date, reports on the actual usage
of psychotropics in AD in clinical settings are few compared with
other countries. Thus, the objective of the present study was to
estimate the frequency of psychotropic use in Japanese AD patients
receiving donepezil hydrochloride, using pooled large real-world
data from Postmarketing Surveillance (PMS) conducted since 1999.2. Methods
2.1. Data source
In the present study, data collected from six prospective, PMS
studies of donepezil hydrochloride in patients with ADwere pooled
and used for analysis. The Japanese regulatory authority obliges
applicants for new drug approval to conduct PMS after approval.
Evidence from clinical trials is obtained in a limited environment.
Therefore, PMS aims to continuously build evidence of the safety
and efﬁcacy of a drug in clinical settings after it has been marketed.
PMS was also mandatory for the approval of donepezil hydro-
chloride. The safety and efﬁcacy of the drug was evaluated by PMS
and it was re-examined.
The pooled PMS data were collected from the following six
studies: ART01S, ART01T, ART02T, ART03T, ART04T, and ART05T
(Table 1). Of the six studies, three studies that had started earlier
than 2005 (ART01S, 01T, and 02T) were conducted in compliance
with the Good Postmarketing Surveillance Practice, a ministerial
ordinance as a guideline for postmarketing pharmacovigilance in
Japan. The other three studies which had started after April 2005
were conducted in compliance with the Good Postmarketing Study
Practice, a ministerial ordinance, due to the replacement of GoodPostmarketing Surveillance Practice with Good Postmarketing
Study Practice in April 2005.
2.2. Patients
The pooled data for this analysis compromised of patients
derived from the safety analysis set in each study. The safety
analysis set was used because it can be assumed that the patients
had received at least one dose of donepezil hydrochloride and had
had at least one postdose safety assessment. A total of 14,729 pa-
tients with AD were identiﬁed in the pooled data. Of them, three of
the patients who had been enrolled in the study before a diagnosis
of AD or who had been suspected of having AD were excluded,
resulting in 14,726 patients included in the analysis.
2.3. Classiﬁcation of psychotropic drugs
In the present study, psychotropics were classiﬁed into the
following ﬁve categories: (1) typical antipsychotics; (2) atypical
antipsychotics; (3) antidepressants; (4) anxiolytics; and (5) hyp-
notics. Typical antipsychotics included chlorpromazine hibenzate,
chlorpromazine hydrochloride, sultopride hydrochloride, sulpiride,
nemonapride, haloperidol, pipamperone hydrochloride, ﬂuphen-
azine, propericiazine, bromperidol, levomepromazine hydrochlo-
ride, and thioridazine hydrochloride (12 drugs). Atypical
antipsychotics included mosapramine hydrochloride, oxypertine,
clocapramine hydrochloride hydrate, zotepine, nortriptyline hy-
drochloride, and quetiapine fumarate (6 drugs). Antidepressants
included amitriptyline hydrochloride, clomipramine hydrochlo-
ride, lofepramine hydrochloride, and lithium carbonate (4 drugs).
Anxiolytics included alprazolam, etizolam, clotiazepam, chlordi-
azepoxide, diazepam, bromazepam, ethyl loﬂazepate, and loraze-
pam (8 drugs). Hypnotics included amobarbital, zopiclone,
nimetazepam, passiﬂora extract, ﬂunitrazepam, brotizolam,
bromvalerylurea, and lormetazepam (8 drugs).
2.4. Clinical assessments
To evaluate the severity of dementia, Functional Assessment
Staging was used. Clinical features were evaluated in Stages 1e7.16
Stage 1 indicates normal, and a higher stage indicates a higher
decline in cognitive function.
Cognitive function was evaluated using the Mini-Mental State
Examination, a 30-point questionnaire with 11 questions.17 A lower
score indicates worse cognitive function. The cognitive impairment
is interpreted according to the following scores:  27 points, none;
< 20 points, moderate; < 10 points, severe.
Language ability was evaluated with The Revised Hasegawa's
Dementia Scale.18 The Revised Hasegawa's Dementia Scale is a 30-
point simple language impairment test consisting of nine ques-
tions. Patients with 20 points or lower are suspected of having
dementia.
2.5. Statistical analysis
Descriptive statistics were calculated for baseline patient and
clinical characteristics. Categorical variables were expressed as
numbers and percentages, while continuous variables were
expressed as mean ± standard deviation (SD), unless otherwise
stated.
The proportion of patients who used psychotropics at least once
during the study period was calculated as the user of psychotropics.
The use of psychotropics was analyzed by dividing patients into
types of psychotropics used, sex, age, and study time period.
Table 1
Summary of study characteristics.
Study Description Registration period n Remarks
ART01S Treatment surveillance study 1999e2002 3541
ART01T Safety & efﬁcacy of administration in AD patients with BPSD 2001e2002 316
ART02T Assessment of impact on ADL & prognosis of discontinued cases 2001e2002 610
ART03T Safety & efﬁcacy of 10-mg administration 2007e2009 843 Severe AD
(FAST Stage 6e7)
ART04T Assessment of family caregiver burden of AD patients 2008e2009 416
ART05T Efﬁcacy of long-term administration 2010e2011 10,238 Mild to moderate AD
(FAST Stage 4e5)
AD ¼ Alzheimer's disease; BPSD ¼ behavioral and psychological symptoms of dementia; FAST¼ Functional Assessment Staging.
Table 2
Baseline patient and clinical characteristics.a
1999e2004
(n ¼ 4115)
2005e2011
(n ¼ 10,611)
Total
(n ¼ 14,726)
Age (y)
Mean ± SD 77.2 ± 8.0 80.1 ± 6.8 79.3 ± 7.2
Sex
Men 1436 (34.9) 3421 (32.2) 4857 (33.0)
Women 2679 (65.1) 7190 (67.8) 9869 (67.0)
Status of donepezil use
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periods for each type of psychotropic.
The mortality percentage of patients who used psychotropics at
least once during the study period and those who did not was
calculated to determine whether there was an increase in the
mortality as warned by the 2005 FDA alert. Patients were also
divided by the study time periods (1999e2004 vs. 2005e2011), and
themortality was calculated for patients who used psychotropics at
least once during the study period and those who did not, to
similarly assess whether there was an increase in the mortality
percentage.
Subsequently, the proportions of psychotropic use by the time
periods were analyzed using Chi-square test to determine whether
population distribution on psychotropic use differs between the
time periods of 1999e2004 and 2005e2011. Furthermore, to
examine the homogeneity of the time period effect on mortality
status (dead or living) in relation to concomitant psychotropic use,
the Breslow-Day test was performed. Additionally, if the estimated
common odds ratios were observed, difference in mortality rate
between concomitant psychotropic users and non-users was
assessed, using the CochraneManteleHaenszel test.
All analyses were conducted using SAS Release 9.3 (SAS Institute
Inc., Cary, NC, USA). All statistical tests were two-tailed and a p
value < 0.05 was considered signiﬁcant.New 4115 (100) 4170 (39.3) 8285 (56.3)
Continued 0 (0.0) 5535 (52.2) 5535 (37.6)
Previously used 0 (0.0) 906 (8.5) 906 (6.2)
Duration of AD (d)
Median (minemax) 518 (0e9290) 609 (0e8466) 586 (0e9290)
Missing 1274 (31.0) 2669 (25.2) 3943 (26.8)
No. of psychotropics
1 671 (16.3) 539 (5.1) 1210 (8.2)
2 300 (7.3) 895 (8.4) 1195 (8.1)
3 181 (4.4) 630 (5.9) 811 (5.5)
None 2963 (72.0) 8547 (80.5) 11,510 (78.2)
FAST
Stage 1 0 (0.0) 0 (0.0) 0 (0.0)
Stage 2 0 (0.0) 0 (0.0) 0 (0.0)
Stage 3 8 (1.4) 3 (0.0) 11 (0.1)
Stage 4 388 (65.9) 6254 (59.0) 6642 (59.3)
Stage 5 165 (28.0) 3500 (33.0) 3665 (32.7)
Stage 6(a)e6(e) 1 (0.2) 763 (7.2) 764 (6.8)
Stage 7(a)e7(f) 0 (0.0) 84 (0.8) 84 (0.8)
MMSE
Mean ± SD 17.9 ± 5.6 18.3 ± 5.4 18.3 ± 5.4
HDS-R
Mean ± SD 14.5 ± 5.7 15.6 ± 5.8 15.6 ± 5.8
Hospital status
Outpatient 3411 (82.9) 9383 (88.4) 12,794 (86.9)
Inpatient 454 (11.0) 633 (6.0) 1087 (7.4)
Doctor's home visit 250 (6.1) 592 (5.6) 842 (5.7)
Unknown 0 (0.0) 3 (0.0) 3 (0.0)
Data are presented as n (%), unless otherwise indicated.
AD ¼ Alzheimer's disease; FAST¼ Functional Assessment Staging; HDS-R ¼ The
Revised Hasegawa's Dementia Scale; MMSE ¼ Mini-Mental State Examination;
SD ¼ standard deviation.
a Summary statistics for MMSE and HDS-R were calculated with missing values
excluded.3. Results
A summary of baseline patient and clinical characteristics is
shown in Table 2. Of a total of 14,726 patients, 67.0% were women.
The mean age (± SD) was 79.3 ± 7.2 years. The median duration of
AD (minimumemaximum) was 586 (0e9290) days. None of the
patients reported the baseline Functional Assessment Staging score
of 1 (no cognitive decline) or 2 (very mild cognitive decline); 0.1%
reported a score of 3 (mild cognitive decline), 59.3% a score of 4
(moderate cognitive decline), 32.7% a score of 5 (slightly severe
cognitive decline), 6.8% a score of 6 (severe cognitive decline), and
0.8% a score of 7 (very severe cognitive decline). The mean Mini-
mental State Examination score (± SD) at baseline was 18.3 ± 5.4.
The percentage of patients who used psychotropics by number of
psychotropics was as follows: 8.2% for one drug, 8.1% for two drugs,
and 5.5% for three or more drugs.
Of the patients, 24.2% used psychotropics concomitantly with
donepezil hydrochloride at least once during the study period
(Table 3). Type of psychotropics used was the highest for hypnotics
(11.0%), followed by typical antipsychotics (7.8%), anxiolytics (6.4%),
antidepressants (5.7%), and atypical antipsychotics (4.4%). The use
of psychotropics was observed in 22.7% of men and 25.0% of women
among 14,726 patients: a slightly higher proportion in women. A
higher use of psychotropics was found in patients < 65 years: 27.6%
for < 65 years, 25.9% for 65e74 years, 23.8% for 75e84 years, and
23.5% for  85 years. The proportion of psychotropic use by the
study time periods was 31.7% for 1999e2004 and 21.3% for2005e2011 (Table 3). As for type of psychotropics used, they
seemingly changed after 2005: from 14.8% to 5.0% for typical an-
tipsychotics, from 3.6% to 4.6% for atypical antipsychotics, from 7.0%
to 5.2% for antidepressants, from 8.1% to 5.7% for anxiolytics, and
from 13.7% to 10.0% for hypnotics.
The mortality rate was 2.6% among those who used psychotro-
pics at least once concomitantly with donepezil hydrochloride
during the study period and 1.8% among those who did not
(Table 4). In studies that enrolled patients between 1999 and 2004,
themortality ratewas 2.3% among thosewho used psychotropics at
least once and 1.7% among those who did not. In studies that
enrolled patients between 2005 and 2011, the mortality rate was
Table 3
Use of psychotropics concomitantly with donepezil hydrochloride by the different time periods.
1999e2004
(n ¼ 4115)
2005e2011
(n ¼ 10,611)
Total
(n ¼ 14,726)
n (%) n (%) n (%)
Patients who used at least 1 type of drug 1303 (31.7)* 2265 (21.3)* 3568 (24.2)
Typical antipsychotics 610 (14.8) 532 (5.0) 1142 (7.8)
Atypical antipsychotics 148 (3.6) 493 (4.6) 641 (4.4)
Antidepressants 287 (7.0) 548 (5.2) 835 (5.7)
Anxiolytics 335 (8.1) 602 (5.7) 937 (6.4)
Hypnotics 564 (13.7) 1058 (10.0) 1622 (11.0)
* A statistical signiﬁcance was observed in the difference in population distribution on psychotropic use between the two time periods (c2 ¼ 172.0, p <0.001).
Table 4
Mortality rate of psychotropic use concomitantly with donepezil hydrochloride by
time period.
1999e2004
(n ¼ 4115)
2005e2011
(n ¼ 10,611)
Total
(n ¼ 14,726)
Used Not used Used Not used Used Not used
Death (n) 30 48 62 157 92 205
% 2.3* 1.7* 2.7* 1.9* 2.6 1.8
Total 1303 2812 2265 8346 3568 11,158
* Breslow-Day test: p ¼ 0.779. CochraneManteleHaenszel test: estimated common
odds ratio: 1.4, 95% conﬁdence interval: 1.1e1.8, p ¼ 0.005.
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among those who did not.
Results of the Chi-square test indicated that a statistical signif-
icance was observed in the proportions of psychotropic use be-
tween the time periods of 1999e2004 and 2005e2011 (31.7% for
1999e2004 vs. 21.4% for 2005e2011, c2 ¼ 172.0, p < 0.001). Given
that population distribution on psychotropic use differs between
the time periods based on the Chi-square test, the Breslow-Day test
was performed; however, evidence for homogeneity in mortality
status in relation to concomitant psychotropic use according to
time period was found (p¼ 0.779). On the other hand, results of the
CochraneManteleHaenszel test rejected that the estimated com-
mon odds ratio for mortality of concomitant psychotropic users and
nonusers was one, indicating that higher mortality rate was more
likely to be observed in concomitant psychotropic users compared
with nonusers (estimated common odds ratio: 1.4, 95% conﬁdence
interval: 1.1e1.8, p ¼ 0.005).
4. Discussion
The present study estimated the frequencies of various types of
psychotropics used in Japanese AD patients who received donepezil
hydrochloride, using the pooled PMS data collected in six studies.
The results found that ~25% of AD patients concurrently used
psychotropics and donepezil hydrochloride. A slightly higher use
was found in women than in men, and a lower use was observed in
older patients. Furthermore, the overall use of psychotropics was
decreased after the warning.
Compared with a prescription-database study previously con-
ducted for Japanese AD, the result of the present study showed a
higher use of psychotropic drugs (vs. 8.9% for antipsychotics).15
However, it seems nearly equivalent to the two percentages
derived from the present study combined (7.8% for typical anti-
psychotics and 4.4% for atypical antipsychotics). As in the previous
study, use of antipsychotics concomitantly with antidementia
drugs appeared lower compared with other countries, such as the
United States and Europe.19e21
In the present study, the proportion of psychotropics used
concomitantly with donepezil hydrochloride was 22.7% for menand 25.0% for women. By contrast, in a Norwegian study, the per-
centage of psychotropic use in combination with an antidementia
drug was varied between the sexes (57.4% in men vs. 65.8% in
women).21 The use of psychotropics was prominently higher in the
Norwegian study compared with the present study. This may be
due to the difference in prescriptions of psychotropic drugs across
the countries. The difference between the studies can be also
explained by the fact that multiple other antidementia drugs other
than donepezil hydrochloride (i.e., rivastigmine, galantamine, and
memantine) and the different combinations of drugs were also
used in the Norwegian study.
Additionally, results demonstrated that as age increased, use of
psychotropics concomitantly with donepezil hydrochloride
decreased. Medication for BPSD became no longer needed probably
because BPSD eventually turns less severe, as generally known.
In the present study, patients were divided into two groups
based on the study time period of the six studies, using the year
2005 as the dividing line. In 2005, the FDA alert that atypical an-
tipsychotics are associated with an increased risk of mortality in
elderly patients treated for dementia-related psychosis was is-
sued.9 The use of psychotropics in the three studies from 2005
onwards decreased by ~10% from that in the three studies up to
2004, with a statistical signiﬁcance, suggesting that patient groups
based on the time periods are from different population groups.
The FDA alert may have contributed to the decrease in use in the
Japanese clinical practice. Similarly, a United States study reported
a small decline in the use of atypical antipsychotics and no evidence
of substitution of other psychotropic medications.19 The Japanese
prescription study previously mentioned above reported no
marked change between the pre- and postwarning periods.15 This
may be because the study duration was different from the present
study and also the majority of patients from the present study were
derived from the latest study, conducted between 2010 and 2011.
The guideline for use of psychotropics for BPSD was issued in 2013
in Japan.13 The current condition of combination use of psycho-
tropics may have been inﬂuenced by the statements in the guide-
lines. The mortality rate in the present study increased by 0.4% in
concomitant psychotropic users in a similar manner to psychotro-
pic nonusers (by 0.2%) after the FDA alert, although no time period
effect was observed in mortality status in relation to concomitant
psychotropic use. A signiﬁcantly higher mortality rate was still
found in concomitant users than nonusers. Compared with our
sample size included in the analysis, the frequency of death is too
low to precisely interpret the results. Moreover, in order to grasp
the actual usage of psychotropics in patients with AD in Japan, PMS
data were pooled for the analysis, but the data were imbalanced
with regards to patient's clinical characteristics as the data
depended upon the original purpose of the studies. Further
research is required for the assessment of concomitant psychotro-
pic use in relation to mortality rates between the pre- and post-
warning periods.
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than prior to 2004, probably because physicians prescribed them
more often as the types of atypical antipsychotics have become
more varied and they are believed to be associated with anticipated
fewer adverse events than conventional typical antipsychotics.
The mortality rate during the study period was slightly lower in
patients who did not use psychotropics. This trend was observed
after dividing the patients into two groups based on the study time
period of 1999e2004 and 2005e2010.
There are some limitations to the present study. Firstly, the
generalizability of the results is limited. The current analysis was
conducted using pooled PMS data to achieve our objective. How-
ever, as stated above, clinical characteristics of AD patients are
varied depending upon the original purpose of each PMS study (e.g.,
severity of AD and new or continuous administration of donepezil).
Thus, results need to be interpreted with caution. Secondly, clinical
characteristics on the presence and severity of BPSD in patients with
AD were not analyzed because this pooled analysis included the
PMS studies which were not originally conducted for the evaluation
of BPSD except for one study (ART01T). Although the presence of
BPSD and that of BPSD symptom type were collected in all studies,
such data were collected only for adverse events in all the studies.
Thirdly, analyses in the present study were conducted by focusing
on psychotropics that were used during the study period since it
was difﬁcult to accurately identify when psychotropics were
administered in some patients. Therefore, psychotropics that had
been started before the surveys were included in the present data.
The prescription database may be effective to identify exactly when
the drugs were prescribed. Fourthly, psychotropics were classiﬁed
into ﬁve categories for the present study. However, the classiﬁca-
tions of the category may vary between countries, and the results
may vary depending on the classiﬁcations. Lastly, the observation
period in the present studywas up to 4 years, the longest in ART04T,
but some studies had 12-week or 12-month observation periods.
Future research with longer observation periods is needed to
examine the mortality rates due to the use of psychotropics in AD
patients administered with donepezil hydrochloride.
In summary, results of the present study using pooled data
demonstrated that one out of four Japanese patients with AD
receiving treatment with donepezil hydrochloride used psycho-
tropics. The percentage of patients using psychotropics tended to
be lower after 2005 compared with earlier than 2004, implicating
that the FDA alert issued in 2005 seemingly have an impact on the
decrease.
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